



ELSEVIER

Contents lists available at ScienceDirect

Cancer Treatment Reviews

journal homepage: www.elsevier.com/locate/ctrv



Corrigendum to “Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors” [Cancer Treatm. Rev. 74 (2019) 21–28]



Stefano Fogli^{a,*}, Marzia Del Re^a, Giuseppe Curigliano^{b,c}, Ron H. van Schaik^d, Patrizio Lancellotti^e, Romano Danesi^a

^a Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

^b Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy

^c Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy

^d European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy

^e Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands

The authors regret an oversight regarding the affiliations. They should have been as stated above.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ctrv.2019.01.006>

* Corresponding author at: Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, 55, Via Roma, 56126 Pisa, Italy.

E-mail address: stefano.fogli@unipi.it (S. Fogli).

<https://doi.org/10.1016/j.ctrv.2019.101913>